Magnesium Sulphate Cooper (Magnesium)

Magnesium Sulphate Cooper is an electrolyte supplement used to manage disorders related to low magnesium levels and associated complications.

• Magnesium deficiency: restores normal serum magnesium concentrations.
• Eclampsia: prevents seizures in pregnant women with severe hypertension.
• Pre‑eclampsia: reduces progression to eclampsia and stabilises blood pressure.
• Torsades de pointes: stabilises cardiac repolarisation to avert ventricular arrhythmias.
• Hypocalcemia: supports calcium homeostasis when magnesium is insufficient.

• Magnesium ions released from the intravenous solution act as essential cofactors for numerous enzymatic reactions, stabilise ATP, modulate calcium channels, and antagonise NMDA receptors. These actions promote vasodilation, reduce neuronal excitability, and correct electrolyte imbalances, thereby addressing the physiological deficits associated with magnesium deficiency and related clinical states.

Adverse reactions may occur with intravenous magnesium administration and vary in frequency and severity.

Common Side Effects

• Flushing or feeling of warmth at the infusion site.
• Transient hypotension due to vasodilatory effect.
• Nausea or mild gastrointestinal discomfort.
• Headache or dizziness during or shortly after infusion.
• Sweating or feeling of heat during administration.

Serious or Rare Side Effects

• Severe hypotension leading to cardiovascular collapse.
• Respiratory depression or apnea, especially with rapid infusion.
• Cardiac arrhythmias, including bradycardia or heart block.
• Hypermagnesemia manifested by muscle weakness, loss of deep tendon reflexes, or paralysis.
• Anaphylactic or severe allergic reactions such as urticaria, bronchospasm, or angioedema.

Intravenous magnesium requires careful assessment and monitoring to minimise risks.

• Renal impairment: adjust dose and monitor serum magnesium closely.
• Cardiac conduction disorders: avoid rapid infusion and observe ECG changes.
• Neuromuscular disease (e.g., myasthenia gravis): monitor for increased weakness.
• Obstetric use: ensure fetal monitoring when administered to pregnant patients.
• Serum monitoring: check magnesium levels before, during, and after therapy.
• Store below 25°C: keep in original container, protect from moisture and light.

Magnesium can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid)

• Calcium channel blockers: additive vasodilatory effect may cause profound hypotension.
• Neuromuscular blocking agents: potentiation can lead to prolonged paralysis.
• Other magnesium‑containing products: risk of hypermagnesemia.
• Aminoglycoside antibiotics: increased risk of neuromuscular blockade.

Moderate Interactions (Monitor Closely)

• Loop and thiazide diuretics: may enhance magnesium loss, requiring dose adjustment.
• ACE inhibitors or ARBs: monitor blood pressure and renal function.
• Digoxin: altered electrolyte balance may affect cardiac contractility.
• Anticoagulants: magnesium may influence coagulation parameters.
• Vitamin D analogues: combined effect on calcium‑phosphate metabolism.